Arrakis Therapeutics

Arrakis Therapeutics is a cutting-edge biotechnology startup that is revolutionizing the field of RNA-targeted small molecule therapeutics, also known as rSM medicines. These are drugs that work by interacting with RNA, a molecule in our cells that plays a crucial role in the production of proteins. By targeting RNA, these drugs can potentially treat a wide range of diseases that are currently difficult to manage.

The company operates in the biotech industry, serving clients such as pharmaceutical companies and research institutions. One of their key partnerships is with Amgen, a multinational biopharmaceutical company, with whom they are working to identify novel RNA degrader small molecule therapeutics. This collaboration is multi-target, meaning it aims to develop drugs that can treat multiple diseases.

Arrakis Therapeutics' business model is based on pioneering new science in the field of rSM medicines. They generate revenue through partnerships with other companies, like Amgen, who are interested in their groundbreaking research and drug development. Additionally, they may also earn income from the sales of any successful drugs that they develop.

The company prides itself on its fearlessness and resilience, and places a strong emphasis on enjoying the journey of scientific discovery. They are always on the lookout for new talent, offering careers in various roles within the company.

Keywords: Biotechnology, RNA-targeted small molecule therapeutics, rSM medicines, Pharmaceutical companies, Research institutions, Amgen, Multi-target collaboration, Drug development, Scientific discovery, Careers.